Safety

Risks of Compounded GLP-1 Medications: What the FDA Says

GLP-1 Companion · 9 min read

For several years, millions of Americans obtained semaglutide or tirzepatide from compounding pharmacies at a fraction of the brand-name cost. This was possible because Ozempic, Wegovy, Mounjaro, and Zepbound were listed on the FDA Drug Shortage List — a designation that created a legal opening for compounders to produce copies. That window has now largely closed, and with it comes a clearer picture of both the legal risks and the genuine safety concerns that always existed.

How the Shortage Created a Legal Gray Area

Federal law generally prohibits compounding pharmacies from copying FDA-approved drugs that are commercially available. However, when a drug is on the FDA Drug Shortage List, an exception applies: compounders may produce copies to address the supply gap. Beginning in 2022, Ozempic and Wegovy (semaglutide) and later Mounjaro and Zepbound (tirzepatide) were all added to the shortage list as demand dramatically outpaced Novo Nordisk and Eli Lilly manufacturing capacity. This exception allowed two categories of compounders to legally produce GLP-1 copies: 503A pharmacies (traditional compounding pharmacies, which fill individual patient prescriptions) and 503B outsourcing facilities (larger FDA-registered compounders producing larger batches for distribution).

During the shortage period, hundreds of telehealth companies partnered with compounding pharmacies to offer GLP-1 medications at prices ranging from $100 to $350 per month — compared to the $900–$1,400 list price of brand-name products. Millions of prescriptions were filled this way.

The FDA Regulatory Timeline: 2025 Onward

The legal landscape changed significantly in 2025 as the FDA began removing GLP-1 drugs from the shortage list.

1. February 2025: The FDA officially removed semaglutide from the Drug Shortage List, determining that Novo Nordisk had resolved the supply shortage. This immediately made compounding of semaglutide at 503A pharmacies (traditional compounders) illegal for most purposes. The legal exception that had allowed copying closed overnight.
2. April 2025: The FDA began sending enforcement letters to major telehealth companies that continued selling compounded semaglutide after the shortage designation ended. Several prominent direct-to-consumer platforms received formal warnings.
3. 503B outsourcing facilities were given a slightly longer wind-down period due to the logistical complexity of halting larger-scale production, but they too were required to cease semaglutide compounding.
4. Late 2025: The tirzepatide shortage was similarly resolved, and the FDA initiated comparable enforcement actions against compounders producing tirzepatide copies.

What Compounding Pharmacies Were Actually Making

Understanding what was actually in compounded GLP-1 products is important for evaluating the safety concerns. The brand-name medications and their compounded counterparts are not chemically identical.

• Brand-name Ozempic and Wegovy use semaglutide sodium — the sodium salt form of the molecule.
• Most compounded semaglutide used semaglutide acetate — a different salt form. The FDA considers these chemically distinct entities.
• Compounded tirzepatide was produced in base or acetate forms, again differing from Eli Lilly's patented formulation.
• Many compounders added unlisted ingredients: cyanocobalamin (B12), vitamin C, BPC-157, or other substances, often marketed as "enhanced" formulas.

The FDA explicitly stated that semaglutide acetate has not been studied for safety or efficacy in the same way as semaglutide sodium, and that no head-to-head comparison exists. The assumption that the two salt forms behave identically in the human body is scientifically unverified.

Documented Safety Risks: What the Evidence Shows

1. Dosing Errors

This was the most serious and most documented risk. The FDA received numerous MedWatch adverse event reports describing patients who had received or self-administered compounded semaglutide at concentrations 5 to 20 times higher than intended. Unlike the pre-filled auto-injector pens used for Ozempic and Wegovy — which deliver a pre-set dose — compounded semaglutide was typically supplied in vials requiring patients to draw up their own dose with a syringe. The concentration of compounded products varied widely across pharmacies, and labeling inconsistencies compounded the problem. A patient accustomed to drawing 0.1 mL from one product could receive a massively different dose if the concentration per mL differed. Reported consequences included severe nausea, vomiting, and hypoglycemia.

2. Contamination Risk

503A compounding pharmacies operate under state pharmacy board oversight, not FDA manufacturing standards. They are not required to meet the same sterility assurance, clean-room standards, potency verification, or batch-testing requirements that govern FDA-approved drug manufacturers like Novo Nordisk and Eli Lilly. Reports of particulate matter in compounded injectable products, non-sterile preparations, and microbial contamination exist in the published literature and FDA warning letters. An injectable product that is not sterile can cause serious infections, including sepsis.

3. Untested Additive Combinations

The practice of adding B12, vitamin C, BPC-157, or other compounds to semaglutide preparations was widespread. None of these combinations have been evaluated for safety or pharmacokinetic interactions. BPC-157, a synthetic peptide, is not FDA-approved for any use in humans and has no established human safety profile. Adding it to a GLP-1 medication creates an entirely unstudied combination — patients were, in effect, unwitting participants in an uncontrolled experiment.

4. No Quality Assurance Infrastructure

FDA-approved GLP-1 medications undergo rigorous quality control: every batch is tested for potency, sterility, and stability. Expiration dates are supported by real shelf-life data. Compounders typically lack this infrastructure. A Certificate of Analysis (CoA) from a third-party lab — when provided at all — tests a sample from a batch, not the entire batch. Potency can vary significantly from vial to vial, and there is no equivalent to a product recall system for most compounded products.

"The FDA is concerned that patients may be misled into thinking that compounded drugs are FDA-approved or that they have been evaluated for safety, effectiveness, and quality — they have not." — FDA Statement on Compounded GLP-1 Medications, 2025

How to Evaluate a Compounding Pharmacy (Where Still Legal)

In limited legal circumstances — such as a documented allergy to an excipient in the brand-name product, a clinical necessity exemption, or access through a 503B facility in a jurisdiction where it remains permissible — some patients may still interact with compounding pharmacies. If you are in this situation, here is how to evaluate quality and minimize risk.

• PCAB Accreditation: The Pharmacy Compounding Accreditation Board (PCAB) accredits compounding pharmacies that meet higher voluntary standards. PCAB accreditation does not guarantee safety, but it indicates the pharmacy has undergone external review.
• 503B Registration: A 503B FDA-registered outsourcing facility is held to significantly higher standards than a traditional 503A pharmacy. They must comply with Current Good Manufacturing Practice (CGMP) regulations and undergo FDA inspections. Always verify 503B status directly on the FDA's website.
• Certificate of Analysis: Request a current CoA for the specific lot you are receiving. It should include third-party testing results for potency, sterility, and endotoxin levels. Refuse any product where this documentation is unavailable.
• Clear Concentration Labeling: The label must state exact concentration in mg/mL and the total volume of the vial. If the concentration is not clearly specified, do not use the product.
• No Unlisted Additives: Verify that the preparation contains only semaglutide (or tirzepatide) and recognized excipients. Refuse preparations containing BPC-157, peptides, or other unapproved additives.

Affordable Alternatives to Compounded GLP-1s

The cost concern that drove many patients to compounding pharmacies is real. However, the affordable access landscape has changed meaningfully since 2025.

• Orforglipron (Foundayo): An oral GLP-1 medication approved by the FDA in April 2026. Available for approximately $25/month with insurance. Unlike injectable GLP-1s, it does not require refrigeration or injection training.
• Oral Wegovy: An oral semaglutide formulation available for approximately $149/month, eliminating injection barriers.
• Lilly's Savings Card: Eligible commercially insured patients can access Zepbound (tirzepatide) for approximately $25/month through Eli Lilly's savings program.
• Novo Nordisk's Savings Card: Eligible patients can access Wegovy for $0–$25/month through Novo's patient savings program.
• Patient Assistance Programs: Both Novo Nordisk and Eli Lilly offer patient assistance programs for uninsured or underinsured patients who meet income requirements.
• GoodRx and Pharmacy Negotiation: Some patients have found meaningful savings on semaglutide through pharmacy discount programs, particularly for the diabetes indication (Ozempic).

The Bottom Line

Compounded GLP-1 medications occupied a legally sanctioned space during the 2022–2025 drug shortage. That space has now closed. The risks that existed during the shortage period — dosing errors, contamination, untested additives, and salt-form differences — did not disappear when the shortage ended; they simply became less justifiable relative to the available alternatives.

If you are currently using compounded semaglutide or tirzepatide obtained from a telehealth service, the most important steps are to verify whether your source is operating legally, to understand exactly what you are injecting and at what concentration, and to discuss transitioning to a brand-name product with your prescriber. The expansion of savings programs and the approval of new oral GLP-1 options means that cost is no longer the insurmountable barrier it once was for many patients.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.